Migraines in children
Migraine Clinical Study for Children 12 to 17 Years of Age
The present phase III clinical study aims to evaluate the efficacy and safety of rimegepant in the treatment of migraine, with or without aura, in children and adolescents aged 12 to 17 years.
To participate in this clinical study, your child must:
- Be between 12 and 17 years old inclusively
- Have 1 to 8 migraines during the last two months and the attacks must last more than 3 hours
- Be able to tell the difference between a headache and a migraine
I want to apply to this clinical study
For more information, contact us at 819 346-2887 (Sherbrooke) or at 1-844-739-3439 (toll free), or fill the online form.
The study process in pictures
Step 1 | Before starting the study, we will take time to fully explain the selection process and the conduct of the study by phone.
Step 2 | After the initial phone interview, if you are still interested in taking part in a study, we schedule a preliminary meeting with you during which you may ask all the questions you wish and take the time you require to read over the consent form. This form explains, in detail, the different stages of each study.
Step 3 | You may make a decision at that time to move forward with or terminate the selection process. However, you are under no obligation to make an immediate decision. Based on briefing content, you may take the time necessary to come to a decision and consult with your personal physician or loved ones.
Step 4 | Depending on the nature of the study, some tests or medical examinations may be required. In the majority of cases, these tests or examinations are conducted on Diex Research premises based on your individual availability.
Step 5 | If you are eligible, you may then begin a clinical study with us.